Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,517 | 361 | 2,119 |
| Samples | 1,054 | 202 | 835 |
| Peptides | 864 | 153 | 724 |
Function
ADAMTS9 · ADAM metallopeptidase with thrombospondin type 1 motif 9
This gene encodes a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protein family. Members of the family share several distinct protein modules, including a propeptide region, a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. Individual members of this family differ in the number of C-terminal TS motifs, and some have unique C-terminal domains. Members of the ADAMTS family have been implicated in the cleavage of proteoglycans, the control of organ shape during development, and the inhibition of angiogenesis. This gene is localized to chromosome 3p14.3-p14.2, an area known to be lost in hereditary renal tumors. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing. [provided by RefSeq, Jan 2016].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 854 amino-acid changes on canonical ENST00000498707 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ADAMTS9 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ADAMTS9 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 7/40 18% | 0/0 0% |
| Chordoma | 2/7 29% | 0/13 0% |
| Oral Cavity Carcinoma | 5/54 9% | 0/0 0% |
| Endometrial Carcinoma | 8/42 19% | 39/612 6% |
| Melanoma | 24/210 11% | 118/1899 6% |
| Glioblastoma | 5/98 5% | 0/0 0% |
| Bladder Carcinoma | 5/58 9% | 35/956 4% |
| Gastric Carcinoma | 3/74 4% | 71/1809 4% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Plasma Cell Myeloma | 7/44 16% | 6/305 2% |
| Colorectal Carcinoma | 30/143 21% | 94/3239 3% |
| Hodgkins Lymphoma | 2/16 12% | 3/122 2% |
| Non-Small Cell Lung Carcinoma | 20/304 7% | 40/1390 3% |
| Other Solid Cancers | 4/94 4% | 44/1515 3% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 22/810 3% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Hepatocellular Carcinoma | 1/46 2% | 47/2210 2% |
| Esophageal Squamous Cell Carcinoma | 8/51 16% | 47/2550 2% |
| Cervical Carcinoma | 2/35 6% | 7/422 2% |
| Non-Cancerous | 0/104 0% | 18/830 2% |
| Neuroendocrine Tumour | 9/154 6% | 5/577 1% |
| Esophageal Carcinoma | 0/23 0% | 14/769 2% |
| Glioma | 0/52 0% | 36/2127 2% |
| Head and Neck Carcinoma | 4/85 5% | 22/1574 1% |
| Other Sarcomas | 5/69 7% | 7/699 1% |
| Germ Cell Tumour | 2/25 8% | 1/169 1% |
| Ovarian Carcinoma | 6/109 6% | 11/998 1% |
| Ewings Sarcoma | 4/63 6% | 1/262 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
Mutation Distribution
Where ADAMTS9 is mutated · all tissues, split by cell line vs tissue
How many mutations in ADAMTS9 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,517 mutations in ADAMTS9
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|